PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.

Tahlia Scheinberg Hui-Ming Lin Michael Fitzpatrick Arun A AzadPaul BonnitchaAmy DaviesGillian Ziona HellerKevin HuynhBlossom MakKate MahonDavid SullivanPeter J Meikle Lisa G Horvath

Published in: Prostate cancer and prostatic diseases (2023)

We have developed PCPro, a lipid biomarker assay capable of prospectively identifying men with mCRPC with a poor prognosis. Prospective clinical trials are required to determine if men who are PCPro positive will benefit from therapeutic agents targeting lipid metabolism.

Keyphrases

poor prognosis
prostate cancer
long non coding rna
clinical trial
fatty acid
middle aged
radical prostatectomy
small cell lung cancer
squamous cell carcinoma
high throughput
cancer therapy
drug delivery
single cell